Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureRuifu Chemical Supply Palbociclib Related Intermediates: Palbociclib CAS 571190-30-2 5-Bromo-2,4-Dichloropyrimidine CAS 36082-50-5 5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine CAS 733039-20-8 tert-Butyl 4-(6-Nitropyridin-3-yl)piperazine-1-Carboxylate CAS 571189-16-7 tert-Butyl 4-(6-Amino-3-Pyridyl)piperazine-1-Carboxylate CAS 571188-59-5 6-Bromo-2-Chloro-8-Cyclopentyl-5-Methylpyrido-[2,3-d]pyrimidin-7(8H)-one CAS 1016636-76-2 2-Chloro-8-Cyclopentyl-5-Methyl-8H-Pyrido[2,3-d]pyrimidin-7-one CAS 1013916-37-4| Item | Specifications |
| Appearance | White to Off-White Powder |
| Purity / Analysis Method | >99.0% (HPLC) |
| 1 H NMR Spectrum | Consistent With Structure |
| Loss on Drying | <1.00% |
| Total Impurities | <1.00% |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Palbociclib (CAS: 571190-30-2) |
Description:
Specifications:
Package & Storage:
| Chemical Name | 5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine |
| Synonyms | N-(5-Bromo-2-Chloropyrimidin-4-yl)(cyclopentyl)amine; 5-Bromo-2-Chloro-4-(Cyclopentylamino)pyrimidine |
| CAS Number | 733039-20-8 |
| CAT Number | RF-PI1851 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C9H11BrClN3 |
| Molecular Weight | 276.56 |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine (CAS: 733039-20-8) can be used as an intermediate of Palbociclib (CAS: 571190-30-2). Palbociclib (trade name: Ibrance) is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib is a kinase inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: An aromatase inhibitor as initial endocrine based therapy in postmenopausal women; or Fulvestrant in women with disease progression following endocrine therapy.
